insulin aspart (Novolog) Report issue

Biologics Recombinant protein Approved FDA
AACT

Active Ingredient History

NOW
  • Now
Insulin aspart, sold under the brand name NovoLog and Fiasp, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is generally used by injection under the skin but may also be used by injection into a vein. Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours. Generally a longer-acting insulin like insulin NPH is also needed.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$2.1480 - $67.3760

Australia

$17.5063 - $30.1979
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

aspartame insulin | insulin aspart / insulin degludec | insulin biasp30

Organizations (66)

Research & Development (66)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

Diabetes Mellitus, Type 2 (approved 2001)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Cystic Fibrosis (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Exercise (Phase 2)

Hyperglycemia (Phase 4)

Hyperkalemia (Phase 4)

Insulin (Phase 2)

Olfaction Disorders (Phase 1)

Pregnancy Complications (Phase 3)

Taste Disorders (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 76
  • # of Trial Organizations: 66

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue